Poster Discussion Session Quality of Life (Qol) with Ribociclib (Rib) plus Aromatase Inhibitor (Ai) Versus Abemaciclib (Abe) plus Ai as First-Line (1L) Treatment (Tx) of Hormone Receptor-Positive/ Human Epidermal Growth Factor Receptor-Negative (Hr+/Her2-) Advanced Breast Cancer (Abc), Assessed via Matching-Adjusted Indirect Comparison (Maic).

AuthID
 P-00X-E9X
11
Author(s)
O'Shaughnessy, J
·
Cardoso, F
·
Bardia, A
·
Maheshwari, VK
·
Tripathi, S
·
Pathak, P
·
Haftchenary, S
·
Fasching, PA
Document Type
Abstract
Year published
2022
Published
in JOURNAL OF CLINICAL ONCOLOGY, ISSN: 0732-183X
Volume: 40, Issue: 16
Indexing
Wos®
Publication Identifiers
Wos: WOS:000863680300072
Source Identifiers
ISSN: 0732-183X
Export Publication Metadata
Marked List
 Add to Marked List
Info
At this moment we don't have any links to full text documens.

A place for researchers and their institutions

Useful Links

Get Help

© 2024 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service